Circulating Tumor Cell (CTC) Market Size & Growth | Report 2028

The circulating tumor cell (CTC) diagnostics market is projected to reach US$ 3,656.38 million by 2028 from US$ 1,909.41 million in 2021; it is estimated to grow at a CAGR of 9.7% from 2021 to 2028.

Circulating tumor cells (CTCs) have tremendous potential in diagnosing and treating cancer. Many techniques have been developed and are under continuous improvement to enhance their efficacy of CTC detection, isolation, enrichment, and analysis. Mostly used approach for CTC detection and isolation is immune-based detection, whereby antibodies selectively bind cell surface antigens. Tumor cells express different cell surface markers than blood cells and are separated from the circulatory cells. CTCs help detect minor subgroups of cells present in the primary tissue, which might eventually cause treatment resistance or relapse of the disease. Hence, detecting and characterizing CTCs can become an inevitable step in treating solid tumor malignancies.

Strategic Insights

The circulating tumor cell (CTC) diagnostics market is segmented on the basis of technology, application, end-user, and geography. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with the analysis of the competitive landscape of the globally leading market players.       

Lucrative Regions for Circulating Tumor Cell (CTC) Diagnostics Market

Get more information on this report : Request Free Sample PDF

Market Insights

Rising Demand for Minimally Invasive Diagnostic Procedures to Drive Circulating Tumor Cell (CTC) Diagnostics Market Growth during Forecast Period

There is a growing preference for minimally invasive or noninvasive procedures among patients for diagnostic purposes. Early cancer detection, mutation detection, tumor monitoring throughout treatment, and recurrence monitoring are possible using circulating tumor cell diagnostics, which uses a noninvasive method. Researchers can trace all epigenetic and genetic changes in solid tumors using blood samples with circulating tumor cells. Patients are at a lesser risk with these tests, and clinicians can readily perform them multiple times. Patients prefer minimally invasive procedures because the advanced instruments used in such procedures allow for more delicate and complex work to be performed with lower risk, less pain, and less scarring.

Due to technological advancements in feasibility and processing times, circulating tumor cell diagnostics and liquid biopsy have recently attracted considerable interest as a noninvasive alternative to tissue biopsy in cancer patients. Liquid biopsy adoption will be aided by an increased understanding of improved minimally invasive cancer detection technologies. The market growth will be influenced by rising demand for noninvasive tools and laboratory acceptance of CTCs tests and liquid biopsy. A liquid biopsy is a noninvasive and simple alternative to surgical biopsies that allows doctors to discover a range of information about tumors from a simple blood sample. Blood tests are painless, noninvasive, bear no risks, and cut down the cost and time to diagnose a problem. In addition, CTCs, cfDNAs, exosomes, and microvesicles can be detected in a blood sample, making blood-based liquid biopsies more popular. Thus, the increased demand for minimally invasive diagnostic tests is spurring the market growth. 

Technology Insights               

Based on technology, the global circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. In 2020, the CTC detection and enrichment segment held the largest share of the market. Moreover, the same segment is expected to register the highest CAGR in the market during 2021–2028. With the help of CTC diagnostics, individuals can be diagnosed early. Therefore, the adaption of these technologies is increasing, which is expected to drive the market during the forecast period.   

Application Insights

Based on application, the global circulating tumor cell (CTC) diagnostics market is bifurcated into clinical/liquid biopsy and research. In 2020, the research segment held a larger share of the market and the same segment is expected to register a higher CAGR in the market during 2021–2028. Owing to the rise in the detection and diagnosis of various medical conditions across the globe, the market is expected to grow in the future.

End-User Insights

Based on end-users, the circulating tumor cell (CTC) diagnostics market is segmented into hospital and clinics, research and academic institutes, and diagnostic centers. The research and academic institutes segment held the largest market share in 2021 and is expected to register the highest CAGR in the market during the forecast period. The increasing research on cancer diagnosis and therapeutic development, growing awareness related to cancer diagnosis, and high investment from government and other enterprises are a few of the critical factors supporting the market growth for the Research and Academic Institutes segment.  

Circulating Tumor Cell (CTC) Diagnostics Market, by Technology – 2021 and 2028

Get more information on this report : Request Free Sample PDF

Product launches, and mergers and acquisitions are highly adopted strategies by the global circulating tumor cell (CTC) diagnostics market players. A few of the recent key market developments are listed below:

• In January 2022, Thermo Fisher Scientific Inc. announced the complete acquisition of PeproTech for a total cash purchase price of approx. US$ 1.85 billion.
• In December 2021, Epic Sciences, Inc. announced the launch of DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw.

The COVID-19 pandemic had a negative impact on the people suffering from cancer and cancer surveillance capacities. Also, due to the pandemic, reduced resources and availability to care made cancer detection and treatment difficult, resulting in higher mortality, and lower survival. Due to a compromised immune system caused by cancer and/or its treatment, cancer patients are susceptible to infectious pathogens (e.g., surgery and chemotherapy). This has raised fears that COVID-19 problems and mortality may be common in cancer patients. Thus, the pandemic negatively impacts the circulating tumor cell (CTC) diagnostics market.

Circulating Tumor Cell (CTC) Diagnostics – Market Segmentation

The global circulating tumor cell (CTC) diagnostics market is segmented on the basis of technology, application, end-user, and geography. In terms of technology, the market is segmented into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. Based on application, the global circulating tumor cell (CTC) diagnostics market is bifurcated into clinical/liquid biopsy and research. Based on end-users, the circulating tumor cell (CTC) diagnostics market is segmented into hospital and clinics, research and academic institutes, and diagnostic centers. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.

Company Profiles

• Thermo Fisher Scientific Inc.
• STEMCELL Technologies Inc.
• QIAGEN
• Precision Medicine Group, LLC.
• Advanced Cell Diagnostics, Inc. (BIO-TECHNE CORPORATION)
• Epic Sciences
• ScreenCell
• Ikonisys, Inc.
• IVDiagnostics
• Fluxion Biosciences Inc0